JP2019510737A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510737A5 JP2019510737A5 JP2018536507A JP2018536507A JP2019510737A5 JP 2019510737 A5 JP2019510737 A5 JP 2019510737A5 JP 2018536507 A JP2018536507 A JP 2018536507A JP 2018536507 A JP2018536507 A JP 2018536507A JP 2019510737 A5 JP2019510737 A5 JP 2019510737A5
- Authority
- JP
- Japan
- Prior art keywords
- fceria
- ige
- lysine
- allergic
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 10
- 239000004472 Lysine Substances 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 9
- 229940024606 amino acid Drugs 0.000 claims 9
- 235000001014 amino acid Nutrition 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 9
- 239000007787 solid Substances 0.000 claims 9
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 6
- 235000004279 alanine Nutrition 0.000 claims 6
- 229960003767 alanine Drugs 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 239000004471 Glycine Substances 0.000 claims 5
- 238000002617 apheresis Methods 0.000 claims 5
- 208000010668 atopic eczema Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 4
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 230000007815 allergy Effects 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 201000008937 atopic dermatitis Diseases 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 235000004400 serine Nutrition 0.000 claims 4
- 229960001153 serine Drugs 0.000 claims 4
- 235000002374 tyrosine Nutrition 0.000 claims 4
- 229960004441 tyrosine Drugs 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- 230000000172 allergic effect Effects 0.000 claims 3
- 230000002327 eosinophilic effect Effects 0.000 claims 3
- 229960002449 glycine Drugs 0.000 claims 3
- 235000014705 isoleucine Nutrition 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims 2
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 2
- 208000005034 Angiolymphoid Hyperplasia with Eosinophilia Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 2
- 208000006343 Cutaneous Mastocytosis Diseases 0.000 claims 2
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 2
- 208000035533 House dust allergy Diseases 0.000 claims 2
- 206010073257 Idiopathic angioedema Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 208000014966 Kimura Disease Diseases 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- 208000007811 Latex Hypersensitivity Diseases 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010033078 Otitis media Diseases 0.000 claims 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 2
- 230000001070 adhesive effect Effects 0.000 claims 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 2
- 230000036783 anaphylactic response Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- 229960005261 aspartic acid Drugs 0.000 claims 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 239000004568 cement Substances 0.000 claims 2
- 210000001198 duodenum Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229920001971 elastomer Polymers 0.000 claims 2
- 210000003979 eosinophil Anatomy 0.000 claims 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 2
- 208000013603 exercise-induced anaphylaxis Diseases 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- 239000003205 fragrance Substances 0.000 claims 2
- 239000000118 hair dye Substances 0.000 claims 2
- 208000013601 idiopathic anaphylaxis Diseases 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 2
- 201000010659 intrinsic asthma Diseases 0.000 claims 2
- 239000004816 latex Substances 0.000 claims 2
- 229920000126 latex Polymers 0.000 claims 2
- 239000010985 leather Substances 0.000 claims 2
- 235000005772 leucine Nutrition 0.000 claims 2
- 229960003136 leucine Drugs 0.000 claims 2
- 208000008585 mastocytosis Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 150000002739 metals Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 231100000614 poison Toxicity 0.000 claims 2
- 208000015768 polyposis Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 238000010992 reflux Methods 0.000 claims 2
- 239000005060 rubber Substances 0.000 claims 2
- 239000002795 scorpion venom Substances 0.000 claims 2
- 230000001932 seasonal effect Effects 0.000 claims 2
- 230000001235 sensitizing effect Effects 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 239000002708 spider venom Substances 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 239000001993 wax Substances 0.000 claims 2
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 102000009438 IgE Receptors Human genes 0.000 claims 1
- 108010073816 IgE Receptors Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039251 Rubber sensitivity Diseases 0.000 claims 1
- 241000239226 Scorpiones Species 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 206010046740 Urticaria cholinergic Diseases 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 208000029407 autoimmune urticaria Diseases 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 201000005681 cholinergic urticaria Diseases 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000002919 insect venom Substances 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 201000005391 latex allergy Diseases 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 230000007096 poisonous effect Effects 0.000 claims 1
- 230000001698 pyrogenic effect Effects 0.000 claims 1
- 239000000700 radioactive tracer Substances 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229940126702 topical medication Drugs 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 231100000611 venom Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020009.3A EP3192806A1 (en) | 2016-01-13 | 2016-01-13 | Alpha chain of the high-affinity ige receptor (fceria) |
| EP16020009.3 | 2016-01-13 | ||
| PCT/EP2017/050646 WO2017121842A1 (en) | 2016-01-13 | 2017-01-13 | Alpha chain of the high-affinity ige receptor (fceria) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019510737A JP2019510737A (ja) | 2019-04-18 |
| JP2019510737A5 true JP2019510737A5 (enExample) | 2020-02-06 |
Family
ID=55357837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018536507A Withdrawn JP2019510737A (ja) | 2016-01-13 | 2017-01-13 | 高親和性ＩｇＥ受容体アルファ鎖（ＦｃｅＲＩａ） |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190127438A1 (enExample) |
| EP (2) | EP3192806A1 (enExample) |
| JP (1) | JP2019510737A (enExample) |
| CN (1) | CN108473551A (enExample) |
| AU (1) | AU2017207854A1 (enExample) |
| CA (1) | CA3010982A1 (enExample) |
| RU (1) | RU2018129024A (enExample) |
| WO (1) | WO2017121842A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113316635A (zh) | 2018-10-29 | 2021-08-27 | 科德克希思公司 | 工程化dna聚合酶变体 |
| CN111100210B (zh) * | 2019-01-30 | 2022-04-19 | 武汉九州钰民医药科技有限公司 | 一种Fc融合蛋白及其应用 |
| MX2022000285A (es) * | 2019-07-08 | 2022-02-03 | Gi Innovation Inc | Dimero de polipeptido con alto contenido de acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige y composicion farmaceutica que comprende el mismo. |
| CN110716054A (zh) * | 2019-09-11 | 2020-01-21 | 天津医科大学 | 一种血清亲细胞性免疫球蛋白e的定量检测试剂盒 |
| FR3108515B1 (fr) * | 2020-03-26 | 2022-03-25 | Ct Hospitalier Universitaire Toulouse | Colonne d’aphérèse pour le traitement de la polyarthrite rhumatoïde |
| US20230279124A1 (en) * | 2020-07-17 | 2023-09-07 | Gi Innovation, Inc. | Fusion protein comprising ige fc receptor alpha subunit extracellular domain and anti-il-4r antibody, and use thereof |
| CN120883058A (zh) * | 2023-03-29 | 2025-10-31 | 基立福环球运营有限公司 | 具有降低的FcεRIβ自身抗体水平的血浆制品的组合物及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06104122B2 (ja) | 1985-09-19 | 1994-12-21 | 東レ株式会社 | β▲下２▼−ミクログロブリン除去カラム |
| US5985599A (en) | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
| US4962035A (en) | 1987-12-01 | 1990-10-09 | President And Fellows Of Harvard College | DNA encoding IgE receptor alpha-subunit or fragment thereof |
| CA2190268C (en) | 1994-05-13 | 2000-01-25 | Wolfgang Bohm | Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood |
| IL116436A (en) * | 1995-12-18 | 2006-12-31 | Yissum Res Dev Co | Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND |
| MY120425A (en) | 1996-07-26 | 2005-10-31 | Novartis Ag | Fusion polypeptides |
| GB9715387D0 (en) | 1997-07-23 | 1997-09-24 | Gould Hannah J | Immunoglobulin-binding polypeptides and their use |
| US6057127A (en) * | 1998-01-29 | 2000-05-02 | Heska Corporation | Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| CA2385778A1 (en) * | 1999-09-21 | 2001-03-29 | Isis Innovation Limited | Modulation of ige receptor cell surface expression |
| WO2002006298A1 (en) * | 2000-07-13 | 2002-01-24 | Hyseq, Inc. | Soluble immunoglobulin e receptor alpha like molecules |
| US8354109B2 (en) | 2005-12-13 | 2013-01-15 | Suppremol Gmbh | Multimeric Fc receptor polypeptides |
| WO2012140214A1 (en) | 2011-04-13 | 2012-10-18 | Biomay Ag | IMMUNOAFFINITY SEPARATION MATERIALS COMPRISING ANTI-IgE ANTIBODY DERIVATIVES |
| CN102660569B (zh) | 2012-04-21 | 2013-11-06 | 大连理工大学 | 一种重组人IgE受体蛋白的制备方法及应用 |
-
2016
- 2016-01-13 EP EP16020009.3A patent/EP3192806A1/en not_active Ceased
-
2017
- 2017-01-13 RU RU2018129024A patent/RU2018129024A/ru not_active Application Discontinuation
- 2017-01-13 AU AU2017207854A patent/AU2017207854A1/en not_active Abandoned
- 2017-01-13 JP JP2018536507A patent/JP2019510737A/ja not_active Withdrawn
- 2017-01-13 CN CN201780005678.0A patent/CN108473551A/zh active Pending
- 2017-01-13 WO PCT/EP2017/050646 patent/WO2017121842A1/en not_active Ceased
- 2017-01-13 US US16/068,406 patent/US20190127438A1/en not_active Abandoned
- 2017-01-13 CA CA3010982A patent/CA3010982A1/en not_active Abandoned
- 2017-01-13 EP EP17700360.5A patent/EP3402813A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510737A5 (enExample) | ||
| RU2018129024A (ru) | Альфа-цепь высокоаффинного рецептора ige (fceria) | |
| US12503501B2 (en) | Treatment of central nervous system disorders by intranasal administration of immunoglobulin G | |
| Ackaert et al. | The impact of nitration on the structure and immunogenicity of the major birch pollen allergen Bet v 1.0101 | |
| RU2013120318A (ru) | Антитела, связывающие il-4 и/или il-13, и их применение | |
| Khan et al. | Complement components as potential therapeutic targets for asthma treatment | |
| BRPI0513798A (pt) | anticorpos anti-cd154 | |
| TW200808821A (en) | Antibody purification | |
| AR058955A1 (es) | Inmunglobulinas que se unen a interleuquina 13 | |
| GEP20115324B (en) | Tweak binding antibodies | |
| Hofer et al. | Tackling Bet v 1 and associated food allergies with a single hybrid protein | |
| CN104066433A (zh) | 药物制剂和其用于治疗花生过敏的用途 | |
| JP2014502253A5 (enExample) | ||
| Rangel-Santos et al. | Immunosuppresive role of principal toxin (crotoxin) of Crotalus durissus terrificus venom | |
| RU2010126590A (ru) | Новые аллергены пшеницы | |
| JP5635771B2 (ja) | 抗炎症性及び抗アレルギー性環状ペプチド | |
| Saavedra et al. | Natural snake venom inhibitors and their pharmaceutical uses: challenges and possibilities | |
| ES2535777T3 (es) | Epítopos antigénicos de la proteína reguladora del factor de virulencia en Staphylococcus aureus y sus mimótopos y uso | |
| AU2002242273C1 (en) | Compositions of multimeric profilin for diagnosis and treatment of allergies | |
| Rossi et al. | Anti-allergic properties of a new all-D synthetic immunoglobulin-binding peptide | |
| JP7158015B2 (ja) | ポリペプチドの凝集化抑制方法 | |
| JP5123858B2 (ja) | ＩｇＥに結合する薬剤 | |
| WO2015077442A2 (en) | Grass pollen immunogens and methods and uses for immune response modulation | |
| WO2015131053A1 (en) | Polypeptides derived from phl p and methods and uses thereof for immune response modulation | |
| JP5981549B2 (ja) | 新規ヒノキ花粉アレルゲンのｔ細胞エピトープペプチド |